Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a common cause of cancer death worldwide. Sorafenib, a multikinase inhibitor, is the first-line drug approved by the Food and Drug Administration (FDA) for the treatment of patients with advanced HCC. However, most patients who continuously receive sorafenib may acq...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Yi-Jen, Hsu, Shih-Ming, Chien, Chia-Ying, Wang, Yuan-Hsi, Hsu, Ming-Hua, Suk, Fat-Moon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355767/
https://www.ncbi.nlm.nih.gov/pubmed/32575795
http://dx.doi.org/10.3390/molecules25122856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355767/
https://www.ncbi.nlm.nih.gov/pubmed/32575795
http://dx.doi.org/10.3390/molecules25122856

Ejemplares similares